Overview

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Phase:

Phase 3

Details

Lead Sponsor:

EpicentRx, Inc.

Collaborator:

Sciclone Pharmaceuticals (China) Co., Ltd.

Treatments:

Carboplatin
Cisplatin
Etoposide